{
  "guideline": {
    "id": "PA166328684",
    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Eliglustat - CYP2D6",
    "objCls": "PGx Association",
    "source": "FDA",
    "version": 0,
    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328684",
    "relatedChemicals": [
      {
        "id": "PA166123486",
        "name": "eliglustat",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA128",
        "name": "cytochrome P450 family 2 subfamily D member 6",
        "symbol": "CYP2D6"
      }
    ],
    "recommendation": false
  },
  "recommendations": [
    {
      "id": "PA166312389",
      "name": "Recommendation Annotation PA166312389",
      "population": "Affected subgroup: CYP2D6 ultrarapid, normal, intermediate, or poor metabolizers",
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166123486",
          "name": "eliglustat",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216669,
        "html": "<p>&quot;Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "2.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166312407",
      "name": "Recommendation Annotation PA166312407",
      "population": "Affected subgroup: CYP2D6 ultrarapid, normal, intermediate, or poor metabolizers",
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166123486",
          "name": "eliglustat",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216706,
        "html": "<p>&quot;Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "3.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166312409",
      "name": "Recommendation Annotation PA166312409",
      "population": "Affected subgroup: CYP2D6 ultrarapid, normal, intermediate, or poor metabolizers",
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166123486",
          "name": "eliglustat",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216708,
        "html": "<p>&quot;Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "≥3.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166312396",
      "name": "Recommendation Annotation PA166312396",
      "population": "Affected subgroup: CYP2D6 ultrarapid, normal, intermediate, or poor metabolizers",
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166123486",
          "name": "eliglustat",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216676,
        "html": "<p>&quot;Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "≥5.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166312403",
      "name": "Recommendation Annotation PA166312403",
      "population": "Affected subgroup: CYP2D6 ultrarapid, normal, intermediate, or poor metabolizers",
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166123486",
          "name": "eliglustat",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216702,
        "html": "<p>&quot;Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "0.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166312387",
      "name": "Recommendation Annotation PA166312387",
      "population": "Affected subgroup: CYP2D6 ultrarapid, normal, intermediate, or poor metabolizers",
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166123486",
          "name": "eliglustat",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216667,
        "html": "<p>&quot;Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "0.75"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166312405",
      "name": "Recommendation Annotation PA166312405",
      "population": "Affected subgroup: CYP2D6 ultrarapid, normal, intermediate, or poor metabolizers",
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166123486",
          "name": "eliglustat",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216704,
        "html": "<p>&quot;Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "1.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166312392",
      "name": "Recommendation Annotation PA166312392",
      "population": "Affected subgroup: CYP2D6 ultrarapid, normal, intermediate, or poor metabolizers",
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166123486",
          "name": "eliglustat",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216672,
        "html": "<p>&quot;Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "2.75"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166312410",
      "name": "Recommendation Annotation PA166312410",
      "population": "Affected subgroup: CYP2D6 ultrarapid, normal, intermediate, or poor metabolizers",
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166123486",
          "name": "eliglustat",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216709,
        "html": "<p>&quot;Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "≥3.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166312423",
      "name": "Recommendation Annotation PA166312423",
      "population": "Affected subgroup: CYP2D6 ultrarapid, normal, intermediate, or poor metabolizers",
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166123486",
          "name": "eliglustat",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216722,
        "html": "<p>&quot;Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "1.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166312412",
      "name": "Recommendation Annotation PA166312412",
      "population": "Affected subgroup: CYP2D6 ultrarapid, normal, intermediate, or poor metabolizers",
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166123486",
          "name": "eliglustat",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216711,
        "html": "<p>&quot;Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "≥4.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166312390",
      "name": "Recommendation Annotation PA166312390",
      "population": "Affected subgroup: CYP2D6 ultrarapid, normal, intermediate, or poor metabolizers",
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166123486",
          "name": "eliglustat",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216670,
        "html": "<p>&quot;Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "2.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166312388",
      "name": "Recommendation Annotation PA166312388",
      "population": "Affected subgroup: CYP2D6 ultrarapid, normal, intermediate, or poor metabolizers",
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166123486",
          "name": "eliglustat",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216668,
        "html": "<p>&quot;Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "1.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166312406",
      "name": "Recommendation Annotation PA166312406",
      "population": "Affected subgroup: CYP2D6 ultrarapid, normal, intermediate, or poor metabolizers",
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166123486",
          "name": "eliglustat",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216705,
        "html": "<p>&quot;Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "1.75"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166312408",
      "name": "Recommendation Annotation PA166312408",
      "population": "Affected subgroup: CYP2D6 ultrarapid, normal, intermediate, or poor metabolizers",
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166123486",
          "name": "eliglustat",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216707,
        "html": "<p>&quot;Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "≥3.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166312404",
      "name": "Recommendation Annotation PA166312404",
      "population": "Affected subgroup: CYP2D6 ultrarapid, normal, intermediate, or poor metabolizers",
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166123486",
          "name": "eliglustat",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216703,
        "html": "<p>&quot;Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "0.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166312422",
      "name": "Recommendation Annotation PA166312422",
      "population": "Affected subgroup: CYP2D6 ultrarapid, normal, intermediate, or poor metabolizers",
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166123486",
          "name": "eliglustat",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216721,
        "html": "<p>Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "0.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166312393",
      "name": "Recommendation Annotation PA166312393",
      "population": "Affected subgroup: CYP2D6 ultrarapid, normal, intermediate, or poor metabolizers",
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166123486",
          "name": "eliglustat",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216673,
        "html": "<p>&quot;Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "4.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166312411",
      "name": "Recommendation Annotation PA166312411",
      "population": "Affected subgroup: CYP2D6 ultrarapid, normal, intermediate, or poor metabolizers",
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166123486",
          "name": "eliglustat",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216710,
        "html": "<p>&quot;Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "≥3.75"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166312413",
      "name": "Recommendation Annotation PA166312413",
      "population": "Affected subgroup: CYP2D6 ultrarapid, normal, intermediate, or poor metabolizers",
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166123486",
          "name": "eliglustat",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216712,
        "html": "<p>&quot;Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "≥6.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166312391",
      "name": "Recommendation Annotation PA166312391",
      "population": "Affected subgroup: CYP2D6 ultrarapid, normal, intermediate, or poor metabolizers",
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166123486",
          "name": "eliglustat",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216671,
        "html": "<p>&quot;Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "2.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    }
  ],
  "citations": [],
  "version": "2024-03-08-14-34"
}